Status:
UNKNOWN
Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
Lead Sponsor:
Second Xiangya Hospital of Central South University
Conditions:
IgA Nephropathy
Eligibility:
All Genders
16-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Multi-glycoside of Tripterygium Wilfordii HOOK. f. is effective and safe in the treatment of IgA nephropathy.
Detailed Description
Primary IgA nephropathy (IgAN) is the most common form of idiopathic glomerulonephritis throughout of the world. The disease is characterized by the predominant deposition of polymer Gal-deficient IgA1...
Eligibility Criteria
Inclusion
- urinary protein levels ≥1.0 g/24 h
- estimated glomerular filtration rate (eGFR) ≥30 ml·min-1·1.73 m-2body surface area by the MDRD formula (eGFR=194×age-0.287×serum creatinine
- 094(×0.739, if female) (where sCr is the serum creatinine, dry chemistry method, mg/dl))
- peripheral blood white blood cell count ≥3000×109/L
- no other cause for tubulointerstitial lesions
- no history of immunomodulatory agent intake before renal biopsy
- no systemic infection
- age between 16 and 65 years
Exclusion
- severe infections
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2015
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02187900
Start Date
June 1 2014
End Date
September 1 2015
Last Update
July 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The second Xiangya Hospital of CSU
Changsha, Hunan, China, 410011